Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes

Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used i...

Full description

Saved in:
Bibliographic Details
Published inExperimental dermatology Vol. 28; no. 7; pp. 786 - 794
Main Authors Lu, Jin, Cong, Tianxin, Wen, Xiang, Li, Xiaoxue, Du, Dan, He, Gu, Jiang, Xian
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes.
AbstractList Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes.
Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta‐hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti‐inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti‐acne properties of SA in human SEB‐1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate‐activated protein kinase (AMPK)/sterol response element‐binding protein‐1 (SREBP‐1) pathway and reduced inflammation by suppressing the NF‐κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB‐1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP‐1 pathway and NF‐κB pathway in human SEB‐1 sebocytes.
Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta-hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti-inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti-acne properties of SA in human SEB-1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate-activated protein kinase (AMPK)/sterol response element-binding protein-1 (SREBP-1) pathway and reduced inflammation by suppressing the NF-κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB-1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP-1 pathway and NF-κB pathway in human SEB-1 sebocytes.Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization of follicular keratinocytes and Propionibacterium acnes (P acnes) overgrowth. Salicylic acid (SA), a beta-hydroxy acid, is frequently used in the treatment of acne. SA has been found to decrease skin lipids and to possess anti-inflammatory properties. However, few studies have elucidated the mechanisms and pathways involved in such treatment of acne. In this study, we initially investigated the anti-acne properties of SA in human SEB-1 sebocytes. Treatment with SA decreased sebocyte lipogenesis by downregulating the adenosine monophosphate-activated protein kinase (AMPK)/sterol response element-binding protein-1 (SREBP-1) pathway and reduced inflammation by suppressing the NF-κB pathway in these cells. Salicylic acid also decreased the cell viability of SEB-1 by increasing apoptosis via the death signal receptor pathway. Subsequently, histopathological analysis of a rabbit ear acne model after application of SA for three weeks confirmed that SA suppressed the levels of cytokines and major pathogenic proteins around acne lesions, which supports the mechanisms suggested by our in vitro experiments. These results initially clarified that therapeutic activities of SA in acne vulgaris treatment could be associated with the regulation of SREBP-1 pathway and NF-κB pathway in human SEB-1 sebocytes.
Author Li, Xiaoxue
Jiang, Xian
Du, Dan
Wen, Xiang
Cong, Tianxin
Lu, Jin
He, Gu
Author_xml – sequence: 1
  givenname: Jin
  surname: Lu
  fullname: Lu, Jin
  organization: Sichuan University
– sequence: 2
  givenname: Tianxin
  surname: Cong
  fullname: Cong, Tianxin
  organization: Sichuan University
– sequence: 3
  givenname: Xiang
  surname: Wen
  fullname: Wen, Xiang
  organization: Sichuan University
– sequence: 4
  givenname: Xiaoxue
  surname: Li
  fullname: Li, Xiaoxue
  organization: Sichuan University
– sequence: 5
  givenname: Dan
  surname: Du
  fullname: Du, Dan
  organization: Sichuan University
– sequence: 6
  givenname: Gu
  orcidid: 0000-0002-1536-8882
  surname: He
  fullname: He, Gu
  email: hegu@scu.edu.cn
  organization: Sichuan University and Collaborative Innovation Center for Biotherapy
– sequence: 7
  givenname: Xian
  surname: Jiang
  fullname: Jiang, Xian
  email: jennyxianj@163.com
  organization: Sichuan University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30972839$$D View this record in MEDLINE/PubMed
BookMark eNpdkVtLw0AQhRep2Is--AdkwRdf0u4lm80-1lovWLFYBd_CJpnUlDSJ2cSaf-_2og8ODOfAfAzDnD7q5EUOCJ1TMqS2RvAdDylX3D1CPeoR4hCPiQ7qEUU8x5NEdFHfmBUhVHIpTlCXEyWZz1UPLRY6S6PWNtZRGuO6Al0b63PAX0221FVqcNhi05RlBcak-RKPn-aPo8XL9HpOcanrj41ucZpjA2ERtTWYU3Sc6MzA2UEH6O12-jq5d2bPdw-T8cxZcVe4jhDUBR6rSPqUMKI0owAgeSJplGgdCYhDQdRWPaJpGAqZKMb9iIIrNfP4AF3t95ZV8dmAqYN1aiLIMp1D0ZiAMSIVF9z1LXr5D10VTZXb6yzlcqY81xeWujhQTbiGOCirdK2rNvh9lwVGe2CTZtD-zSkJtjkENodgl0Mwfb_ZGf4DaKp6aw
ContentType Journal Article
Copyright 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Copyright_xml – notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
– notice: 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
DBID NPM
7T5
H94
K9.
NAPCQ
7X8
DOI 10.1111/exd.13934
DatabaseName PubMed
Immunology Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitle PubMed
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList AIDS and Cancer Research Abstracts

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1600-0625
EndPage 794
ExternalDocumentID 30972839
EXD13934
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 21772131; 81872535
– fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province
  funderid: 2019YFSY0004; 2017JY0075
– fundername: National Natural Science Foundation of China
  grantid: 21772131
– fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province
  grantid: 2019YFSY0004
– fundername: National Natural Science Foundation of China
  grantid: 81872535
– fundername: the Fundamental Research Funds of Science & Technology Department of Sichuan Province
  grantid: 2017JY0075
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1OB
1OC
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACUHS
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFWVQ
AFZJQ
AHBTC
AHEFC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
CYRXZ
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
FZ0
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TUS
UB1
V8K
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
YFH
YUY
ZZTAW
~IA
~WT
AGHNM
NPM
7T5
AAMMB
AEFGJ
AEYWJ
AGXDD
AGYGG
AIDQK
AIDYY
H94
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-j3454-5514e3d9c7810209a21eee73f71cfaac5edb509c5ed60a1bb57f9238c1e47a263
IEDL.DBID DR2
ISSN 0906-6705
1600-0625
IngestDate Fri Jul 11 00:28:57 EDT 2025
Fri Jul 25 10:13:03 EDT 2025
Thu Apr 03 07:08:07 EDT 2025
Wed Jan 22 16:42:06 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords NF-κB
acne vulgaris
salicylic acid
sebocyte
inflammation
SREBP-1
Language English
License 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-j3454-5514e3d9c7810209a21eee73f71cfaac5edb509c5ed60a1bb57f9238c1e47a263
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-1536-8882
PMID 30972839
PQID 2243296485
PQPubID 2045157
PageCount 9
ParticipantIDs proquest_miscellaneous_2207935348
proquest_journals_2243296485
pubmed_primary_30972839
wiley_primary_10_1111_exd_13934_EXD13934
PublicationCentury 2000
PublicationDate July 2019
PublicationDateYYYYMMDD 2019-07-01
PublicationDate_xml – month: 07
  year: 2019
  text: July 2019
PublicationDecade 2010
PublicationPlace Denmark
PublicationPlace_xml – name: Denmark
– name: Chichester
PublicationTitle Experimental dermatology
PublicationTitleAlternate Exp Dermatol
PublicationYear 2019
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2004; 101
1997; 336
2015; 18
2000; 28
2017; 26
2000; 25
2018; 106
2015; 468
2015; 51
2002; 99
2008; 9
2016; 74
2008; 34
2008; 128
2002; 82
2008; 74
2003; 19
2015; 8
2007; 57
2018; 27
2016; 36
2016; 12
1998; 37
2004; 113
2015; 135
2017; 35
2004; 292
2015; 21
2002; 129
2013; 133
2008; 118
2014; 13
2018; 74
2006; 126
2012; 336
2016; 25
2016; 9
2005; 14
References_xml – volume: 14
  start-page: 143
  year: 2005
  publication-title: Exp. Dermatol.
– volume: 51
  start-page: 13113
  year: 2015
  publication-title: Chem. Commun.
– volume: 336
  start-page: 918
  year: 2012
  publication-title: Science
– volume: 133
  start-page: 429
  year: 2013
  publication-title: J. Invest. Dermatol.
– volume: 128
  start-page: 1286
  year: 2008
  publication-title: J. Invest. Dermatol.
– volume: 74
  start-page: S5
  issue: suppl
  year: 2008
  publication-title: Indian J. Dermatol. Venereol. Leprol.
– volume: 27
  start-page: 993
  year: 2018
  publication-title: Exp. Dermatol.
– volume: 28
  start-page: 27
  year: 2000
  publication-title: Nucleic Acids Res.
– volume: 101
  start-page: 11245
  year: 2004
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 126
  start-page: 2178
  year: 2006
  publication-title: J. Invest. Dermatol.
– volume: 9
  start-page: 40
  year: 2016
  publication-title: J. Clin. Aesthet. Dermatol.
– volume: 25
  start-page: 25
  year: 2000
  publication-title: Nat. Genet.
– volume: 74
  start-page: 414
  year: 2018
  publication-title: Acta Biomater.
– volume: 19
  start-page: 1
  year: 2003
  publication-title: Adv. Dermatol.
– volume: 118
  start-page: 1468
  year: 2008
  publication-title: J. Clin. Investig.
– volume: 9
  start-page: 955
  year: 2008
  publication-title: Expert Opin. Pharmacother.
– volume: 27
  start-page: 30
  year: 2018
  publication-title: Exp. Dermatol.
– volume: 25
  start-page: 477
  year: 2016
  publication-title: Exp. Dermatol.
– volume: 82
  start-page: 104
  year: 2002
  publication-title: Acta Derm. Venereol.
– volume: 113
  start-page: 1168
  year: 2004
  publication-title: J. Clin. Investig.
– volume: 99
  start-page: 7148
  year: 2002
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 74
  start-page: 945
  year: 2016
  publication-title: J. Am. Acad. Dermatol.
– volume: 34
  start-page: 45
  year: 2008
  publication-title: Dermatol. Surg.
– volume: 18
  start-page: 723
  year: 2015
  publication-title: Cell Host Microbe
– volume: 336
  start-page: 1156
  year: 1997
  publication-title: N. Engl. J. Med.
– volume: 468
  start-page: 125
  year: 2015
  publication-title: Biochem. J.
– volume: 21
  start-page: 18100
  year: 2015
  publication-title: Chemistry
– volume: 126
  start-page: 1226
  year: 2006
  publication-title: J. Invest. Dermatol.
– volume: 36
  start-page: 983
  year: 2016
  publication-title: Med. Res. Rev.
– volume: 8
  start-page: 455
  year: 2015
  publication-title: Clin. Cosmet. Investig. Dermatol.
– volume: 13
  start-page: 15
  year: 2014
  publication-title: J. Cosmet. Dermatol.
– volume: 35
  start-page: 179
  year: 2017
  publication-title: Clin. Dermatol.
– volume: 57
  start-page: 222
  year: 2007
  publication-title: J. Am. Acad. Dermatol.
– volume: 135
  start-page: 1491
  year: 2015
  publication-title: J. Invest. Dermatol.
– volume: 106
  start-page: 1727
  year: 2018
  publication-title: Biomed. Pharmacother.
– volume: 25
  start-page: 701
  year: 2016
  publication-title: Exp. Dermatol.
– volume: 129
  start-page: 933
  year: 2002
  publication-title: Ann. Dermatol. Venereol.
– volume: 292
  start-page: 726
  year: 2004
  publication-title: JAMA
– volume: 26
  start-page: 798
  year: 2017
  publication-title: Exp. Dermatol.
– volume: 12
  start-page: 1540
  year: 2016
  publication-title: Mol. BioSyst.
– volume: 37
  start-page: 335
  year: 1998
  publication-title: Int. J. Dermatol.
SSID ssj0017375
Score 2.4803717
Snippet Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over‐keratinization...
Acne vulgaris is a prevalent cutaneous disease characterized by a multifactorial pathogenic process including hyperseborrhea, inflammation, over-keratinization...
SourceID proquest
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 786
SubjectTerms Acids
Acne
acne vulgaris
Adenosine kinase
AMP
Apoptosis
Cell viability
Cytokines
Inflammation
Keratinization
Keratinocytes
Kinases
Lipids
Lipogenesis
NF‐κB
Protein kinase
Salicylic acid
sebocyte
Skin
SREBP‐1
Sterol regulatory element-binding protein
Title Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP1 pathway in sebocytes
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fexd.13934
https://www.ncbi.nlm.nih.gov/pubmed/30972839
https://www.proquest.com/docview/2243296485
https://www.proquest.com/docview/2207935348
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PS-QwFH6IB_Gy649dd9SVLOzBS8fWJE2DJ11HZBdFnBXmsFCSNJFR6IidquNf70vaKe6yB_FQGkgK7Ute3pe-L18AvssCgwbNXCSdDGlGLKWGRbGQBiNSVmgX2Bbn6ekV-zniowU4mO-FafQhuh9u3jPCfO0dXOnqlZPbp6KP8IV6LVDP1fKA6LKTjkoEDSK7scQVcypi3qoKeRZP9-T_UOXfIDVEmZOP8Gf-fg255LZfT3XfPP8j3fjOD1iBDy36JIfNcFmFBVuuwdJZm19fh-FQeZlgvIgy44IEGnqF5dKSh9rv-hhXRM9IVd81BNrymhyeXfzaG14Oji4S4s83flQzMi5JhROZmSGQ_QRXJ4PfP06j9tiF6IYyziKPoSwtpBEZoo9Yqv3EWiuoE4lxShluC40ww9_TWCVac-EQJmYmsUyo_ZR-hsVyUtovQBRLCpfFxmHQY0oVWaw4E1pyK5gzMunB9rwD8tZ3qhxBBfXJ4Iz34FtXjaPepzJUaSe1b-OF_ThlWQ82mo7L7xp5jpx6RSLEfT3YDebvKubrHTR8HgyfD0bHobD59qZbsIyYSTaM3W1YnN7X9ivikqneCQPwBQj23N4
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3Pb9MwFH4aQwIujN8rjGEkkLikJLUdxwcOG-3U0XWa1k3qLTiOjbpJ2bQ0jPI37V_hf9qzk0YMceCyA4colmxFsZ-f32f782eAdzLHoEETG0gr_TYjpmLNglBIjREpyTPr2Rb78fCYfZny6QpcLc_C1PoQ7YKb8ww_XjsHdwvSv3m5-ZF3Eb9Q1lAqR2ZxiRO28tNuH637vtfbGRx9HgbNnQLBCWWcBQ4gGJpLLRIMraFUvcgYI6gVkbZKaW7yDGOoe8ehirKMC4sYKNGRYUL1YorfvQN33Q3iTqm_f9iKVUWCelnfUOIcPRYhb3SMHG-o_dW_4dibsNjHtZ01-LVskZrOctqt5llX__xDLPJ_abJH8LAB2GSr9ojHsGKKJ3Bv3FAInsJkopwSMj5E6VlOPNO-xHRhyPfKHWyZlSRbkLI6rznCxTeyNT4YfZwcDrYPIuKucL5UCzIrSIljtV4gVn8Gx7dSpeewWpwVZh2IYlFuk1BbjOtMqTwJFWcik9wIZrWMOrCxtHjaDA9liriJuv3uhHfgbZuNju12a1RhzipXxmkXcsqSDryoe0p6XiuQpNSJLiG07cAHb-82YzmlQ0On3tDpYNr3iZf_XvQN3B8ejffSvd390St4gBBR1gTlDVidX1TmNcKwebbpez-Br7fdd64BZaY7QQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtQwFL0qRarY8H4MFDASSGwyJGM7jhcsCjOjlqHVqEOl2QXHDzStlI7IhDL8Er_CR3HtZCJALNh0wSKKpWtFia-v73F8fAzwXBpMGjRzkXQyLDNiKdUsioXUmJEyU7jAtjhK90_Yuzmfb8H3zV6YRh-i--HmIyOM1z7Al8b9EuT2q-kjfKGsZVRO7PoC52vV64MhOvfFYDAefXi7H7VHCkSnlHEWeXxgqZFaZJhZY6kGibVWUCcS7ZTS3JoCU6i_p7FKioILhxAo04llQg1Sis-9AldZGkt_TsTwuNOqSgQNqr5oSKNUxLyVMfK0oe5V_wZjf0fFIa2Nb8CPTYM0bJazfr0q-vrbH1qR_0mL3YTrLbwme0083IItW96GncOWQHAHZjPldZDxIkovDAk8-wrLpSVfar-tZVGRYk2qetkwhMtPZO9wOnk1Ox69mSbEH-B8odZkUZIKR2q9RqR-F04u5ZPuwXZ5XtoHQBRLjMti7TCrM6VMFivORCG5FcxpmfRgd-PwvB0cqhxRE_Wr3RnvwbPOjGHt12pUac9rX8crF3LKsh7cbzpKvmz0R3LqJZcQ2PbgZXB3Z9hM6NDReXB0PpoPQ-Hhv1d9CjvT4Th_f3A0eQTXEB_Khp28C9urz7V9jBhsVTwJfZ_Ax8vuOj8BWo858A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Salicylic+acid+treats+acne+vulgaris+by+suppressing+AMPK%2FSREBP1+pathway+in+sebocytes&rft.jtitle=Experimental+dermatology&rft.au=Lu%2C+Jin&rft.au=Cong%2C+Tianxin&rft.au=Wen%2C+Xiang&rft.au=Li%2C+Xiaoxue&rft.date=2019-07-01&rft.issn=0906-6705&rft.eissn=1600-0625&rft.volume=28&rft.issue=7&rft.spage=786&rft.epage=794&rft_id=info:doi/10.1111%2Fexd.13934&rft.externalDBID=10.1111%252Fexd.13934&rft.externalDocID=EXD13934
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0906-6705&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0906-6705&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0906-6705&client=summon